FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, specifically to a conjugate of an antibody specific to CAPRIN-1 protein or its antigen-binding fragment with an immune activator. The invention allows for obtaining a new conjugate of an anti-CAPRIN-1 antibody with immune activators, in particular with TL7/8 agonists – reziquimod or its derivatives, that has significantly stronger antitumor effect compared to immunoconjugates known from the technology level.
EFFECT: invention can be used in medicinal practice as a drug in the treatment of malignant neoplasms expressing CAPRIN-1 protein on the surface of cell membrane.
12 cl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
ANTIBODY TO HUMAN CD73 | 2017 |
|
RU2754058C2 |
IMMUNE TOLERANCE INDUCING ANTIBODIES, INDUCED LYMPHOCYTES AND THERAPEUTIC AGENT/METHOD OF CELL THERAPY USING INDUCED LYMPHOCYTES | 2019 |
|
RU2816592C2 |
ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES | 2017 |
|
RU2781148C2 |
PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT TUMOUR | 2016 |
|
RU2714205C2 |
CHO-SE-9/4 CELL STRAIN, PRODUCER OF CHIMERIC HUMAN ERYTHROPOIETIN ANTIBODY AND CHIMERIC ANTIBODY PRODUCED BY SAID STRAIN | 2019 |
|
RU2717038C1 |
ANTIBODY AGAINST HUMAN FN14 | 2019 |
|
RU2787044C2 |
MATERIALS AND METHODS USED FOR TREATMENT OF RESPIRATORY DISEASES IN DOGS | 2020 |
|
RU2811752C2 |
KLK5-INHIBITING PEPTIDE | 2019 |
|
RU2826422C2 |
INFLUENZA VIRUS CAPABLE OF INFECTING CANINES AND ITS USE | 2020 |
|
RU2802222C2 |
Authors
Dates
2022-03-15—Published
2017-10-27—Filed